ARCA biopharma to merge with Oruka Therapeutics.

ARCA biopharma, a clinical-stage biopharmaceutical company, to merge with Oruka Therapeutics, a biotechnology company developing novel biologics. “Our mission at Oruka is to offer people affected with chronic skin diseases the most possible freedom from their condition. We believe that our lead programs, engineered by the world-class team at Paragon, could meaningfully advance the standard of care in psoriasis and related diseases. This merger and significant financing is expected to provide resources to build out our operational capabilities and propel our programs into clinical development with focus and efficiency,” Lawrence Klein, Oruka CEO.